信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

农历年初二休市 02-16 12:08:06

89.100

+0.500

+0.56%

最高89.900	最低87.700	成交量352.97万
今开88.950	昨收88.600	日振幅2.48%
总市值1,546亿	流通市值1,546亿	总股本17.35亿
成交额3.13亿	换手率0.20%	流通股本17.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":89.1,"timestamp":1771214886004,"preClose":88.6,"halted":0,"volume":3529691,"delay":0,"changeRate":0.0056433408577878106,"floatShares":1735000000,"shares":1735000000,"eps":-0.06810222743259085,"marketStatus":"农历年初二休市","change":0.5,"latestTime":"02-16 12:08:06","open":88.95,"high":89.9,"low":87.7,"amount":312557003,"amplitude":0.024831,"askPrice":89.1,"askSize":36000,"bidPrice":89,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.7657686861430246,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":88.6,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0.5829632213744801,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.4866,"impliedVolPercentile":0.2209},"requestUrl":"/m/hq/s/01801/wiki","defaultTab":"wiki","newsList":[{"id":"2611104750","title":"每日卖空追踪 | 信达生物 02月16日卖空量成交65.75万股，卖空比例为18.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611104750","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611104750?lang=zh_cn&edition=full","pubTime":"2026-02-16 16:30","pubTimestamp":1771230621,"startTime":"0","endTime":"0","summary":"信达生物北京时间02月16日，涨0.56%，卖空量成交65.75万股，较上一交易日减少72.42%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163237a700de68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163237a700de68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2097828631.EUR","BK1589","LU2242644610.SGD","LU2097828474.EUR","BK1583","LU0455707207.USD","LU2097828805.USD","LU0502904849.HKD","LU2328871848.SGD","LU1969619763.USD","LU2097828557.USD","HK0000165453.HKD","01801","BK1161","LU2097828714.EUR"],"gpt_icon":0},{"id":"2611819632","title":"每日卖空追踪 | 信达生物 02月13日卖空量成交127万股，卖空比例为12.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611819632","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611819632?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:30","pubTimestamp":1770971426,"startTime":"0","endTime":"0","summary":"信达生物北京时间02月13日，跌0.51%，卖空量成交127万股，较上一交易日减少38.41%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213163322a49ff8aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213163322a49ff8aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU0502904849.HKD","LU2242644610.SGD","LU2097828631.EUR","HK0000165453.HKD","LU2097828557.USD","LU2097828474.EUR","BK1589","LU2488822045.USD","LU1969619763.USD","01801","LU2097828714.EUR","LU0455707207.USD","LU2328871848.SGD","BK1583","BK1161"],"gpt_icon":0},{"id":"2611319634","title":"没有“熟果”？信达生物超88亿美元BD，不走常规路","url":"https://stock-news.laohu8.com/highlight/detail?id=2611319634","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611319634?lang=zh_cn&edition=full","pubTime":"2026-02-13 09:44","pubTimestamp":1770947078,"startTime":"0","endTime":"0","summary":"根据协定条款，信达生物将获得3.5亿美元首付款，在达成后续特定里程碑事件后，还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。消息一出，资本市场反响热烈，信达生物股价一度大涨超7%。因此，信达生物与礼来的BD合作，本质是双方各取所长的深化布局。信达生物近期发布的一份公告提到，2025年公司实现产品收入119亿元，同比增长45%，首次突破百亿元大关，主要得益于综合产品线发展强劲。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213094505a49e8d91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213094505a49e8d91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01801","LU2097828714.EUR","LU2488822045.USD","LU2097828474.EUR","LU2097828557.USD","LU1969619763.USD","LU2328871848.SGD","BK1583","BK1589","LU2097828805.USD","LU2242644610.SGD","LU0502904849.HKD","HK0000165453.HKD","LU0455707207.USD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2610232499","title":"信达生物隐忧：主营见顶，第二曲线价格战","url":"https://stock-news.laohu8.com/highlight/detail?id=2610232499","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610232499?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:00","pubTimestamp":1770897634,"startTime":"0","endTime":"0","summary":"3月在即，司美格鲁肽核心专利将在国内到期，一场看不见硝烟的争夺已然箭在弦上。丁香园Insight数据库显示，目前已有10款国产司美格鲁肽申报上市，另有11款进入III期临床。仿制药大量上市后，价格战似乎不可避免。而这对信达生物（01801.HK）绝非好消息。2025年6月，信达生物旗下玛仕度肽注射剂获批上市，一个强有力的新玩家正式加入竞争激烈的GLP-1红海赛道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123649413749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828474.EUR","LU2328871848.SGD","LU2097828714.EUR","LU0502904849.HKD","LU0455707207.USD","LU2242644610.SGD","BK1583","LU2097828557.USD","LU2097828631.EUR","BK1161","HK0000165453.HKD","LU1969619763.USD","BK1589","LU2097828805.USD","LU2488822045.USD","01801"],"gpt_icon":0},{"id":"2610200947","title":"摩根大通增持信达生物(01801)58.59万股 每股作价约79.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610200947","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610200947?lang=zh_cn&edition=full","pubTime":"2026-02-12 19:22","pubTimestamp":1770895378,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，2月6日，摩根大通增持信达生物(01801)58.59万股，每股作价79.232港元，总金额约为4642.2万港元。增持后最新持股数目约为8721.76万股，最新持股比例为5.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","IE00B1XK9C88.USD","IE00BHPRN162.USD","LU1145028129.USD","LU2237443622.USD","LU1116320901.HKD","LU0203345920.USD","LU0265550946.USD","LU2552382215.SGD","LU2264538146.SGD","BK4534","LU0971096721.USD","LU1119994496.HKD","IE0034235295.USD","LU2097828714.EUR","LU0345770308.USD","LU2328871848.SGD","LU0345769631.USD","LU0964807845.USD","LU0006306889.USD","LU1244550577.SGD","BK4516","IE00B775SV38.USD","LU2097828805.USD","01801","LU2236285917.USD","LU0787776722.HKD","LU1551013425.SGD","LU2054465674.USD","LU1496350502.SGD","LU0106831901.USD","BK4533","LU2456880835.USD","LU2746668461.USD","IE00BKDWB100.SGD","LU0203347892.USD","LU1280957306.USD","LU2746668974.SGD","LU1668664300.SGD","LU2213496289.HKD","IE00BJTD4N35.SGD","BK4207","IE00BFXG1179.USD","LU2106854487.HKD","LU1894683348.USD","LU0106261372.USD","LU2097828474.EUR","LU0256863811.USD","LU0320765646.SGD","LU2430703178.SGD"],"gpt_icon":0},{"id":"2611979257","title":"信达生物02月12日主力净流出6344.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2611979257","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611979257?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:15","pubTimestamp":1770884159,"startTime":"0","endTime":"0","summary":"02月12日, 信达生物股价跌0.67%，报收89.05元，成交金额9.0亿元，换手率0.59%，振幅3.46%，量比0.73。信达生物今日主力资金净流出6344.5万元，上一交易日主力净流入867.0万元。该股近5个交易日上涨9.20%，主力资金累计净流入1.6亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1253.9万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212162151a49b917f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212162151a49b917f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","01801","HK0000165453.HKD","LU0455707207.USD","LU2097828557.USD","LU2097828631.EUR","LU2097828805.USD","LU2328871848.SGD","LU2097828474.EUR","BK1589","BK1161","LU2488822045.USD","BK1583","LU1969619763.USD","LU2097828714.EUR","LU0502904849.HKD"],"gpt_icon":0},{"id":"2611297925","title":"【券商聚焦】中泰国际上调信达生物目标价至136港元 指海外授权加速全球化","url":"https://stock-news.laohu8.com/highlight/detail?id=2611297925","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611297925?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:02","pubTimestamp":1770861777,"startTime":"0","endTime":"0","summary":"金吾财讯|中泰国际发布研报指，信达生物与美国礼来达成第七次合作，获得3.5亿美元首付款及最高85亿美元里程碑付款，同时与日本武田的12亿美元授权协议已生效。公司预计2025年产品销售收入同比增45%至119亿元人民币，其中第四季度增速超60%。三款重点药物IBI363、IBI343和IBI324的全球III期临床进展有望成为股价催化剂。该行将2025-27E收入预测上调0.3%/16.4%/9.7%，净利润预测调整为9.8亿/35.5亿/27.5亿元人民币，基于DCF模型将目标价上调至136港元，维持\"买入\"评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212101106a49a41a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212101106a49a41a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801"],"gpt_icon":0},{"id":"2611792669","title":"瞩目，信达生物重磅降脂新药又有新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2611792669","media":"北京药研汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611792669?lang=zh_cn&edition=full","pubTime":"2026-02-12 08:01","pubTimestamp":1770854519,"startTime":"0","endTime":"0","summary":"心血管疾病是威胁人类安全的头号杀手。因此降低LDL-C水平，可显著减少ASCVD的发病及死亡危险。托莱西单抗，作为信达生物自主研发的IgG2全人源单克隆抗体，能够特异性地与PCSK9分子结合。此次，信达生物按治疗用生物制品注册分类2.2类申报的托莱西单抗注射液，进一步扩展了该药的适应症，必将为广大患者提供更多的治疗选择，期待早日获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021210090497a5de41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021210090497a5de41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","LU2097828557.USD","LU2242644610.SGD","LU2097828631.EUR","LU0502904849.HKD","LU2097828474.EUR","LU0455707207.USD","LU1969619763.USD","LU2328871848.SGD","LU2097828714.EUR","LU2097828805.USD","01801","LU2488822045.USD","BK1161","BK1589","BK1583"],"gpt_icon":0},{"id":"2610295213","title":"每日卖空追踪 | 信达生物 02月11日卖空量成交62.55万股，卖空比例为7.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610295213","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610295213?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:30","pubTimestamp":1770798626,"startTime":"0","endTime":"0","summary":"信达生物北京时间02月11日，股价较前一交易日持平，卖空量成交62.55万股，较上一交易日减少82.12%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163314a6ee1d1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163314a6ee1d1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","LU2097828805.USD","BK1161","LU2488822045.USD","LU2328871848.SGD","LU2242644610.SGD","BK1583","LU0455707207.USD","LU2097828474.EUR","01801","LU0502904849.HKD","LU2097828557.USD","LU2097828631.EUR","BK1589","LU1969619763.USD","LU2097828714.EUR"],"gpt_icon":0},{"id":"2610558939","title":"信达生物战略合作属正面惊喜，目标价111港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610558939","media":"摩根大通","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610558939?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:15","pubTimestamp":1770797748,"startTime":"0","endTime":"0","summary":"这一合作被摩根大通视为正面惊喜，标志着信达生物在迈向全球性生物制药公司的过程中迈出了重要一步。摩根大通对信达生物在其商业及研发产品线上的执行力表示高度认可，并对其业务拓展能力给予了积极评价。该行给予信达生物“增持”评级，并将其目标价设定为111港元。总体来看，这次合作被视为信达生物发展历程中的一个重要里程碑，值得投资者密切关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163141a4972dcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163141a4972dcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801"],"gpt_icon":0},{"id":"2610893956","title":"口服GLP-1成热门赛道！华东医药、信达生物、德睿智药、恒瑞医药等加速竞逐","url":"https://stock-news.laohu8.com/highlight/detail?id=2610893956","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610893956?lang=zh_cn&edition=full","pubTime":"2026-02-11 15:52","pubTimestamp":1770796351,"startTime":"0","endTime":"0","summary":"在国产口服GLP-1管线中，华东医药、信达生物、德睿智药、恒瑞医药等企业的产品进度较快。通过高效特异性靶向激活GLP-1R，引发级联信号转导，从而延缓胃排空、抑制食欲、促进胰岛素分泌，达到治疗肥胖、2型糖尿病等胰岛素相关代谢疾病的目的。同时，已有多款国产GLP-1药物达成海外授权，彰显了国产创新药的国际认可度。随着临床研究的持续推进，国产口服GLP-1药物有望惠及更多代谢性疾病患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211155455a6edf1a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211155455a6edf1a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828631.EUR","LU2097828805.USD","01801","LU0455707207.USD","LU1023057109.AUD","LU2097828474.EUR","BK1583","LU0359202008.SGD","LU2543165471.USD","01276","LU2328871848.SGD","BK1161","LU1969619763.USD","LU0359201885.HKD","LU2242644610.SGD","HK0000165453.HKD","LU2097828557.USD","LU2488822045.USD","BK1191","BK1589","LU0359201612.USD","LU2097828714.EUR","LU0502904849.HKD"],"gpt_icon":0},{"id":"2610521659","title":"130亿医药大佬，拿下600多亿大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2610521659","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610521659?lang=zh_cn&edition=full","pubTime":"2026-02-11 08:51","pubTimestamp":1770771069,"startTime":"0","endTime":"0","summary":"同花顺iFinD数据显示，2018年至2024年，信达生物累计归母净利润亏损规模超过145亿元。在去年10月公布的《2025胡润百富榜》上，俞德超以130亿元的身家位列榜单第528名，财富较2024年上涨160%。11年7次合作，信达生物再获礼来大单根据协定条款，此次信达生物与礼来达成的合作，信达生物将获得3.5亿美元首付款。公告显示，2025年，信达生物总产品收入增长约45%，达到约119亿元，这也是公司有史以来产品收入首次突破百亿大关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211085547a6ec76a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211085547a6ec76a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2328871848.SGD","LU0502904849.HKD","LU2097828714.EUR","LU0455707207.USD","LU1969619763.USD","LU2097828557.USD","01801","LU2242644610.SGD","09939","BK1574","LU2097828631.EUR","BK1589","BK1515","LU2097828805.USD","BK1583","LU2097828474.EUR","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2610608006","title":"【券商聚焦】中泰国际重申信达生物(01801)“买入”评级 指重磅海外授权交易顺利推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2610608006","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610608006?lang=zh_cn&edition=full","pubTime":"2026-02-11 08:37","pubTimestamp":1770770249,"startTime":"0","endTime":"0","summary":"该机构根据2025年第四季度的产品销售情况微调2025-27E的产品销售收入预测，并将礼来与武田的首付款纳入收入预测，因此将2025-27E的收入预测分别上调0.3%、16.4%与9.7%，并将2025-27E股东净利润预测分别上调3.6%、244.9%与54.3%，主要反映新增授权费的贡献。根据调整后DCF模型，目标价上调至136.00港元，重申“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974911","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"gpt_icon":0},{"id":"2610402116","title":"信达生物与礼来“双向奔赴”，中国药企全球化新范式？","url":"https://stock-news.laohu8.com/highlight/detail?id=2610402116","media":"药经说","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610402116?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:31","pubTimestamp":1770715882,"startTime":"0","endTime":"0","summary":"日前，信达生物发布公告，宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。以信达与礼来的BD为例，信达主要承担药物研发及中国市场商业化职能，全球市场权益均归属于礼来。当阿斯利康与石药集团签署185亿美元的减肥药协议，当百济神州的泽布替尼在全球市场斩获超10亿美元销售额，中国药企的全球化已不可逆转。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210200731a4938c1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210200731a4938c1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","LU2097828557.USD","LU2242644610.SGD","LU2097828631.EUR","LU0502904849.HKD","LU2097828474.EUR","LU0455707207.USD","LU1969619763.USD","LU2328871848.SGD","LU2097828714.EUR","LU2097828805.USD","01801","LU2488822045.USD","BK1161","BK1589","BK1583"],"gpt_icon":0},{"id":"2610487645","title":"加速全球化布局：英硅智能联手康哲药业、信达生物88.5亿美元出海、复方丹参滴丸美国梦碎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610487645","media":"中国粉体网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610487645?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:29","pubTimestamp":1770715757,"startTime":"0","endTime":"0","summary":"中国粉体网讯1、英硅智能：与康哲药业达成药物研发战略合作2月10日英硅智能发布公告，其已与康哲药业达成药物研发战略合作。这是中国首款、全球第二款进入临床的VAV1分子胶降解剂。根据协议条款，公司将获得3.5亿美元首付款；在达成后续特定里程碑事件后，还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210172925a492f653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210172925a492f653&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999015978.USD","IE00BMCWC346.EUR","SG9999015986.USD","01801","IE00BVYPNP33.GBP","LU1969619763.USD","LU2097828805.USD","00867","SG9999015952.SGD","IE00BVYPNQ40.USD","LU2097828631.EUR","LU0502904849.HKD","03696","BK1583","LU2097828557.USD","BK1161","SG9999015945.SGD","BK1593","LU2242644610.SGD","LU2097828714.EUR","BK1191","HK0000165453.HKD","IE00BGHQDM52.EUR","IE00BYV24P56.USD","LU2097828474.EUR","LU0455707207.USD","SG9999004220.SGD","BK1589","LU2328871848.SGD","LU2488822045.USD"],"gpt_icon":1},{"id":"2610692360","title":"大行评级丨小摩：重申信达生物为生物科技行业首选标的之一，与礼来合作属正面惊喜","url":"https://stock-news.laohu8.com/highlight/detail?id=2610692360","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610692360?lang=zh_cn&edition=full","pubTime":"2026-02-10 12:07","pubTimestamp":1770696422,"startTime":"0","endTime":"0","summary":"摩根大通发表研报指，信达生物与礼来达成战略合作，共同在全球范围开发聚焦于肿瘤和免疫学领域的新型生物制剂。该行认为此次合作属正面惊喜，标志着信达生物迈向全球性生物制药公司历程中的又一个重要里程碑，并突显其研发平台的实力。在电话会议上，信达生物管理层重申其长期愿景，主要受惠于通用生物药和肿瘤药领域双引擎增长策略的支持。该行对信达生物在其商业及研发产品在线的执行力，以及其强大的业务拓展能力持续印象深刻。该行重申信达生物是其所覆盖的中国生物科技公司中的首选标的之一，予其“增持”评级，目标价为111港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260210/32009444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IE00BJT1NW94.SGD","LU0820561909.HKD","LU0006306889.USD","SG9999015978.USD","LU2168563687.JPY","LU2361045086.USD","LU0689472784.USD","LU2471134952.CNY","IE00B4JS1V06.HKD","01801","LU0256863811.USD","LU2237438978.USD","LU2097828805.USD","LU2552382215.SGD","LU2111349929.HKD","LU2237443895.HKD","BK4534","IE0002141913.USD","LU2552382132.HKD","IE00B2B36J28.USD","LU0094547139.USD","IE00BKDWB100.SGD","LU0385154629.USD","LU2089283258.USD","LU1551013425.SGD","LU2097828631.EUR","LU2213496289.HKD","LU1548497426.USD","LU2756315664.SGD","LLYX","SGXZ81514606.USD","LU2168564065.EUR","LU2756315318.SGD","LU1988902786.USD","LU0106261372.USD","LU0353189763.USD","LU0820562030.AUD","LU2746668974.SGD","LU2360106947.USD","IE00B775H168.HKD","LU0158827781.USD","LU2097828557.USD","LU2237443622.USD","IE00B7KXQ091.USD","LU0432979614.USD","BK1161","IE00BJJMRZ35.SGD","LU2023250504.SGD","LU2112291526.USD","BK4007","IE0004445015.USD","LU2168564495.EUR","LU1868836914.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0471298777.SGD","BK1589","BK4585","LU0683600562.USD","LU2328871848.SGD","LU1366192091.USD","IE00BN29S564.USD","SG9999014898.SGD","LU0353189680.USD","IE00B1XK9C88.USD","BK4581","LU1720051108.HKD","BK4599","LU0114720955.EUR","LU1023059063.AUD","LU2491050071.SGD","LU0234572021.USD","LU0058720904.USD","LU0238689110.USD","LU2028103732.USD","LU0708995401.HKD","LU0823416689.USD","LU2089984988.USD","LU2462157665.USD","LU1093756325.SGD","LU0097036916.USD","LU2491049909.HKD","LU0109391861.USD","LU0316494557.USD","IE00BK4W5L77.USD","LU1061106388.HKD","LU1127390331.HKD","IE00BJJMRX11.SGD","IE00BK4W5M84.HKD","LU0787776722.HKD","LU2023250330.USD","BK1583","LU0203201768.USD","LU2324357040.USD","SG9999014906.USD","LU1868837300.USD","LU2471134523.USD","LU1093756168.USD","SG9999001176.USD","LU0061475181.USD","LU2750360997.AUD","LU1291159041.SGD","LU2097828714.EUR","HK0000165453.HKD","LU1551013342.USD","LU2023251221.USD","LU0225283273.USD","LU2106854487.HKD","LU0823434740.USD","LU1035775433.USD","LU2361044865.SGD","LU0640476718.USD","LU0823434583.USD","LU1280957306.USD","LU0471298694.HKD","LU0323591593.USD","SGXZ31699556.SGD","LU0122379950.USD","LU0289739699.SGD","LU1145028129.USD","LU2063271972.USD","LU2089284900.SGD","LU2471134879.HKD","LU0417517546.SGD","LU2552382058.USD","ELIS","LU0256863902.USD","LU2211815571.USD","LU0158827948.USD","LU2491050154.USD","LU1969619763.USD","SG9999001176.SGD","IE0005OL40V9.USD","IE00BJLML261.HKD","LU1064131342.USD","LU2461242641.AUD","ELIL","BK4588","LU0882574139.USD","IE00B1BXHZ80.USD","LU1868836591.USD","LU2271345857.HKD","IE00BJJMRY28.SGD","LU0456855351.SGD","LU1623119135.USD","LU0203202063.USD","BK4516","LU1267930730.SGD","LU1804176565.USD","LU2264538146.SGD","LU2456880835.USD","LU0672654240.SGD","SG9999013999.USD","SG9999018865.SGD","SGXZ57979304.SGD","LU0354030511.USD","SG9999015945.SGD","LU0354030438.USD","BK4533","SG9999017495.SGD","LU1814569148.SGD","LU1629891620.HKD","LU2242644610.SGD","IE00BWXC8680.SGD","LU2750360641.GBP","LU2361044949.HKD","LU2468319806.SGD","LU2087625088.SGD","IE00BFSS7M15.SGD","LU2237443382.USD","LU2097828474.EUR","LU2237443978.SGD","LU1323610961.USD","LU1868836757.USD","SG9999014880.SGD","LU0198837287.USD","LU2108987350.USD","LU2746668461.USD","IE00BKPKM429.USD","LU0882574055.USD","SGXZ99366536.SGD","LU2471134796.USD","LU0964807845.USD","LU0109394709.USD","LU2357305700.SGD","IE0004445239.USD","LU0320765059.SGD","IE00BFSS8Q28.SGD","SG9999015986.USD","LLYZ","LU2265009873.SGD","LU2896262040.SGD","LU2168564222.USD","LU2237443465.HKD","SGXZ51526630.SGD","LU0889565916.HKD","SG9999015952.SGD","LU2417539215.USD","LU0096364046.USD","LU0820561818.USD","LU2602419157.SGD","LU0502904849.HKD","IE00BFTCPJ56.SGD","LU2168564149.EUR","SG9999014914.USD","LU1989771016.USD","GB00BDT5M118.USD","LU1057294990.SGD","LU1868837136.USD","IE0009355771.USD","LU0466842654.USD","LU1917777945.USD","LU1720051017.SGD","LU2237443549.SGD","LU1069344957.HKD","LU1712237335.SGD","LU0079474960.USD","LU1974910355.USD","LU0266013472.USD","LU0210536198.USD","LU2236285917.USD","LU0943347566.SGD","LU1232071149.USD","SG9999018857.SGD","LU0786609619.USD","LU0455707207.USD","LU1983299246.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2610969486","title":"创新药概念震荡反弹 高增长潜力概念股出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2610969486","media":"腾讯自选股综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610969486?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:17","pubTimestamp":1770693474,"startTime":"0","endTime":"0","summary":"创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。华源证券指出，经历短期波动消化后，创新药板块已显现企稳回暖迹象。整体上，国金证券认为创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。从未来增长潜力来看，多股获机构预测2026年净利增速有望翻倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01513","02228","06185","00867","06160","01801","BK1574","BK1515","00013","02196","01093","01276","01952","01548","02096","BK1583","02269","00512","06978","03692","01877","01177"],"gpt_icon":0},{"id":"2610364071","title":"85亿！信达与礼来，第七次合作！","url":"https://stock-news.laohu8.com/highlight/detail?id=2610364071","media":"药融CDMO之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610364071?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:04","pubTimestamp":1770692690,"startTime":"0","endTime":"0","summary":"2026年2月8日，信达生物宣布，公司正式与礼来制药达成一项全新的战略合作协议，旨在携手推进肿瘤及免疫领域创新药物的全球研发。根据双方签署的合作协议，信达生物与礼来将充分发挥各自的互补优势，通过构建无缝衔接的端到端创新生态体系，加快创新药物在全球范围内的研发工作。信达生物与礼来的首次合作，可以追溯到2015年3月，当时双方决定共同在中国开发和商业化至少三种肿瘤治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210132750a49207c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210132750a49207c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2097828805.USD","BK1589","LU2242644610.SGD","LU2097828557.USD","BK1161","LU0455707207.USD","BK1583","LU0502904849.HKD","LU2097828631.EUR","LU2097828714.EUR","LU2488822045.USD","LU2097828474.EUR","01801","LU2328871848.SGD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2610991156","title":"【券商聚焦】海通国际：信达生物(01801)与礼来的合作规模超预期 充分发挥公司国内高效的临床能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2610991156","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610991156?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:56","pubTimestamp":1770692180,"startTime":"0","endTime":"0","summary":"根据协议条款，信达生物将获得 3.5 亿美元首付款；在达成后续特定里程碑事件后，信达生物还有资格获得总额最高约 85 亿美元的研发、监管及商业化里程碑付款。该机构指，这是信达与礼来的第七次合作，该合作规模超预期。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"34f23f16691bc3dd0945b028f8bb922f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974850","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIS","IE00B7KXQ091.USD","LU1093756168.USD","LU2097828474.EUR","LU2357305700.SGD","IE00BJJMRZ35.SGD","LU2471134796.USD","BK4599","IE00BFSS7M15.SGD","LU0820561909.HKD","LU1551013342.USD","LU2456880835.USD","LU0203202063.USD","LU2213496289.HKD","LU1868837300.USD","LU1868837136.USD","SG9999018857.SGD","LU0316494557.USD","LU2023250504.SGD","IE00BJLML261.HKD","LU0114720955.EUR","LU2089984988.USD","LU2756315664.SGD","LU0943347566.SGD","LU0823434583.USD","LU2028103732.USD","IE00B1BXHZ80.USD","LU0256863811.USD","LU0456855351.SGD","IE00BWXC8680.SGD","LU0471298777.SGD","LU2237443465.HKD","LU0689472784.USD","LU2750360641.GBP","LU2112291526.USD","LU1232071149.USD","01801","LU2265009873.SGD","LU0353189763.USD","LU2237443978.SGD","LU0320765059.SGD","LU1023059063.AUD","LU0094547139.USD","BK4581","LU0466842654.USD","LU0234572021.USD","IE00BN29S564.USD","LU2168563687.JPY","LU1093756325.SGD","LU0882574139.USD","IE00B4JS1V06.HKD","IE0009355771.USD","LU0708995401.HKD","LU2236285917.USD","LU2491050071.SGD","BK1161","SG9999014898.SGD","SG9999015945.SGD","LU2168564149.EUR","LU0672654240.SGD","LLYZ","LU0820562030.AUD","LU0097036916.USD","LU1323610961.USD","SGXZ31699556.SGD","LU1712237335.SGD","LU2417539215.USD","LU2468319806.SGD","LU1061106388.HKD","SG9999017495.SGD","BK4534","LU1291159041.SGD","LU1974910355.USD","LU2471134952.CNY","LU2361045086.USD","LU2462157665.USD","LU2756315318.SGD","SG9999015952.SGD","IE00B4R5TH58.HKD","LU0109391861.USD","LU2264538146.SGD","BK4007","LU1551013425.SGD","LU0786609619.USD","IE00BJT1NW94.SGD","LU1145028129.USD","LU2063271972.USD","LU2237438978.USD","LU2896262040.SGD","IE00BFTCPJ56.SGD","SG9999018865.SGD","IE0002141913.USD","LU1127390331.HKD","GB00BDT5M118.USD","IE00B2B36J28.USD","IE00B775H168.HKD","LU2111349929.HKD","LU2168564065.EUR","LU2237443895.HKD","LU2168564495.EUR","LU2750360997.AUD","IE00BKDWB100.SGD","LU2097828631.EUR","LU0882574055.USD","LU1629891620.HKD","LU2552382058.USD","LU0640476718.USD","LU0683600562.USD","LU0471298694.HKD","LU2108987350.USD","LU2023250330.USD","BK4533","LU2089284900.SGD","LU2461242641.AUD","LU2097828557.USD","LU1623119135.USD","LU2746668461.USD","SG9999014914.USD","LU2471134879.HKD","LU0210536198.USD","LU2271345857.HKD","LU2360106947.USD","LU2168564222.USD","LU0787776722.HKD","IE00BJJMRX11.SGD","LU0320765992.SGD","LU0502904849.HKD","IE0004445015.USD","LU0823416689.USD","LU1720051108.HKD","LU0198837287.USD","LU1366192091.USD","SG9999015986.USD","LU0122379950.USD","LU2324357040.USD","SG9999001176.USD","LU0266013472.USD","LU2097828714.EUR","SG9999015978.USD","BK1583","HK0000165453.HKD","LU0820561818.USD","LU1868836914.USD","LU0964807845.USD","LU0889565916.HKD","LU2361044949.HKD","LU1064131342.USD","LU1069344957.HKD","LU2237443622.USD","SG9999013999.USD","BK1589","SGXZ99366536.SGD","LU2242644610.SGD","LU2106854487.HKD","LU2089283258.USD","IE00BK4W5L77.USD","LU0455707207.USD","LU2746668974.SGD","LU2491050154.USD","LU1267930730.SGD","LU0158827781.USD","LU1988902786.USD","LU0061475181.USD","LU0385154629.USD","LU0323591593.USD","LU0823434740.USD","LU2602419157.SGD","SGXZ57979304.SGD","LU1814569148.SGD","LU0106261372.USD","LU2471134523.USD","LU0225283273.USD","LU0058720904.USD","LU1280957306.USD","BK4588","LU0432979614.USD","BK4585","LU2087625088.SGD","LU2237443382.USD","LU2097828805.USD","LU2237443549.SGD","IE00BK4W5M84.HKD","LU0203201768.USD","LU2211815571.USD","LU1057294990.SGD","LU1804176565.USD","LU0006306889.USD","LU1868836591.USD","LU1720051017.SGD","SG9999014906.USD","LU0289739699.SGD","LU1989771016.USD","SG9999014880.SGD","SG9999001176.SGD","ELIL","LU1035775433.USD","LU0354030438.USD","LU1548497426.USD","IE00BJJMRY28.SGD","IE0005OL40V9.USD","LU2491049909.HKD","LU1983299246.USD","LU2552382215.SGD","LU2361044865.SGD","LU2328871848.SGD","LU0109394709.USD","LU0256863902.USD","LU1917777945.USD","LU2488822045.USD","SGXZ51526630.SGD","LU0354030511.USD","LU0079474960.USD","BK4516","LU0353189680.USD","LU0238689110.USD","LU1969619763.USD","IE0004445239.USD","LU2023251221.USD","LU2552382132.HKD","LLYX","LU1868836757.USD","LU0096364046.USD","SGXZ81514606.USD","IE00BKPKM429.USD","LU0417517546.SGD","LU0158827948.USD","IE00BFSS8Q28.SGD","IE00B1XK9C88.USD"],"gpt_icon":0},{"id":"2610972836","title":"信达生物高额出海催化，创新药ETF涨1.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610972836","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610972836?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:54","pubTimestamp":1770692054,"startTime":"0","endTime":"0","summary":"截至2月10日10点20分，上证指数涨0.24%，深证成指涨0.24%，创业板指涨0.23%。影视院线、知识产权保护、文化传媒等板块涨幅居前。消息上，信达生物与礼来公司达成一项总付款高达88.5亿美元的全球战略合作，这是近期中国创新药企达成的高额海外授权交易。这一事件进一步验证了中国创新药企的研发实力与国际竞争力，是创新药板块出海逻辑的重要催化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210105719a6e87cb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210105719a6e87cb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","LU0455707207.USD","LU2097828631.EUR","BK1583","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","LU2097828474.EUR","BK1161","LU2328871848.SGD","LU1969619763.USD","LU2097828805.USD","LU0502904849.HKD","HK0000165453.HKD","01801","LU2097828714.EUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0433},{"period":"1month","weight":-0.0045},{"period":"3month","weight":-0.0144},{"period":"6month","weight":-0.0586},{"period":"1year","weight":1.376},{"period":"ytd","weight":0.1685}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0052},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0612},{"period":"1year","weight":0.1806},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.116691},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}